In old, frail, type-2 diabetes HFpEF patients, circulating miR-92 levels were upregulated compared to age-matched healthy controls, and the levels were reduced 3 months after treatment with SGLT-2 inhibitor empagliflozin (122). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.